Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Curatolo

Anesthesiology Dover, NH Medical Doctor

NPI 1285900100 CMS profile 1374785

789 Central Ave, Dover, NH 03820

Open in the dashboard

General payments

$6,057

94 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Curatolo of Dover, NH is reported in the CMS Open Payments database as having received $6,057 across 94 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $459 15
2024 General $1,307 21
2023 General $712 8
2022 General $2,164 20
2021 General $516 7
2020 General $324 4
2019 General $575 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Curatolo
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Christopher Curatolo were reported at $459. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Christopher Curatolo Anesthesiology median Middle half National median
2019 $575 $72 $23–$151 $163
2020 $324 $36 $17–$120 $114
2021 $516 $49 $21–$135 $132
2022 $2,164 $52 $22–$144 $149
2023 $712 $53 $23–$143 $160
2024 $1,307 $55 $25–$150 $164
2025 $459 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $3,647 57 payments
  2. Nevro Corp. $574 8 payments
  3. Vertos Medical, Inc. $320 3 payments
  4. Abbott Laboratories $298 2 payments
  5. Nalu Medical, Inc. $272 2 payments
  6. SPR Therapeutics, Inc $269 3 payments
  7. Saluda Medical Americas, Inc. $186 2 payments
  8. Pacira Pharmaceuticals Incorporated $167 2 payments
  9. Merck Sharp & Dohme Corporation $123 3 payments
  10. Medtronic USA, Inc. $94 5 payments
  11. Other $107 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,141 87 payments
  2. Travel and Lodging $900 6 payments
  3. Education $15 1 payment
Products named General payments · program years 2019–2025
  1. Superion Indirect Decompression System $1,436 14 payments
  2. General - Pain Management General - Pain Management_NMD $453 12 payments
  3. WaveWriter Alpha Prime 16 $323 4 payments
  4. mild Device Kit $320 3 payments
  5. Senza Spinal Cord Stimulation System $295 6 payments
  6. Omnia $279 2 payments
  7. Nalu Neurostimulation System $272 2 payments
  8. SPRINT PNS System $269 3 payments
  9. GENERAL - PAIN MANAGEMENT Pain Management $221 2 payments
  10. Evoke $186 2 payments
  11. Other $1,347 30 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

228

Median for Anesthesiology: 322

Drug cost

$3,275

Median for Anesthesiology: $8,738

Branded share of claims

19.7%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 32 $696
Pregabalin Generic 31 $619
Gabapentin Generic 36 $544
Oxycodone Hcl Generic 24 $400
Morphine Sulfate Er Morphine Sulfate Brand 13 $295
Cyclobenzaprine Hcl Generic 24 $242
Tizanidine Hcl Generic 23 $241
Tramadol Hcl Generic 32 $211
Cephalexin Generic 13 $27

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$60,408

Medicare's payments for the services billed

Medicare patients

258

Average age 72

Services billed

749

166 women, 92 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 38%
Diabetes 30%
Ischemic heart disease 26%
Heart failure 21%
Atrial fibrillation 21%
Chronic kidney disease 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

94 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in New Hampshire

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record